Protective mutation impairs oesophagus tumour growth
Cells carrying mutations in the NOTCH1 gene take over the human oesophagus by middle age but inhibit oesophageal tumour growth in mice, suggesting a route to prevent cancer.
A protective mutation found in most cells in the human oesophagus reduces tumour growth in mice, potentially highlighting new ways to prevent or treat cancer in similar tissues.
Researchers, from the Wellcome Sanger Institute and collaborators, visualised cells with mutations in the NOTCH1 gene, finding most cells in the human oesophagus have these mutations above age 50. This is surprising, as very few oesophageal cancers have NOTCH1 mutations and suggests NOTCH1 is an advantageous mutation.
The new study, published today (19 January 2023) in Nature Genetics, uncovered that the loss of NOTCH1 gives cells an advantage over their neighbours, enabling them to push out other cells, and take over normal tissue. The same mutation impairs the growth of tumours in mice.
Further research into why NOTCH1 mutations confer a protective effect could shed light on new ways to prevent the growth of cancer in the oesophagus as well as in similar tissues, such as the mouth lining. Therapies that block the action of NOTCH1 may also have therapeutic potential in treating cancers, if the results are shown to be the same in humans.
Over time, all cells in the body acquire genetic mutations, and while the majority of these do not affect how the cell functions, some give an advantage that allows those cells to grow at a faster rate. Sometimes, mutations cause uncontrollable growth leading to cancer and the formation of tumours.
By middle age, the human oesophagus evolves into a patchwork of mutated cells. While the majority of these mutations do not lead to cancer, if tumours do form, they can be hard to treat as symptoms appear when the cancer has started to spread.
Oesophageal cancer is the sixth leading cause of cancer deaths globally, with more than 500,000 new cases diagnosed annually and an overall five-year survival rate below 30 per cent.1 There are two types — oesophageal adenocarcinoma and oesophageal squamous cell carcinoma — with the latter accounting for approximately 85 per cent of all cases worldwide. This type is less frequent in the UK and more common in Eastern Asia, and Southern and Eastern Africa.1
While mutations in genes such as TP53 are found in almost all oesophageal squamous cell carcinoma tumours, mutations in the NOTCH1 gene are relatively rare in these cancers despite being very common in normal oesophagus tissue, suggesting NOTCH1 mutants may protect against cancer.
In this new study, researchers from the Wellcome Sanger Institute and collaborators genetically analysed samples of normal oesophageal epithelium from middle-aged and elderly donors and found frequent NOTCH1 mutations affecting both copies of the gene and inactivating its function.
Using mice models, the team found that cells containing a Notch1 mutation spread throughout the tissue but then reverted to near normal behaviour. When tumours are formed by treating mice with a chemical from tobacco, Notch1 mutants spread over the normal oesophagus but slowed tumour growth. In addition to this, a NOTCH1 blocking antibody reduced tumour growth.
NOTCH1 inhibitors are in clinical development for certain types of cancer. Understanding more about how NOTCH1 mutations function could help uncover new ways to prevent tumours from forming.
“Our study shows that the loss of function mutation in Notch1 is beneficial in that it takes over the oesophagus but helps to slow the growth of potentially cancerous cells in mice. Our research highlights the importance of studying somatic mutations in both tumours and normal tissues to improve our understanding of their role in cancer development.”
Dr Emilie Abby, first author from the Wellcome Sanger Institute
“More than 9,200 people are diagnosed with oesophageal cancer in the UK every year. Unfortunately, many patients present with later stage cancer, when the disease tends to be more advanced and harder to treat. This study presents new insights into the role that common NOTCH1 mutations may play in early cancer development, and raises important questions around how efforts to specifically target these alterations could be explored as new ways to prevent, detect and treat oesophageal cancer in the future.”
Dr Sam Godfrey, Research Information lead at Cancer Research UK, who part funded the study
“The oesophagus is a Darwinian battleground, with cells competing against each other for space, giving novel insight into how mutations change cell behaviour. Studying these mutations can lead to a further understanding of how cancers develop and possibly hold the key to preventing the disease from happening, or developing new ways to treat it. Oesophageal squamous cell carcinoma is a devastating disease, with symptoms usually only developing when the cancer has already begun to spread. Further investigation of how positive mutations, such as those in NOTCH1, interfere with tumour growth could be the key to understanding how to prevent this cancer from forming at all in the future.”
Dr Phil Jones, senior author from the Wellcome Sanger Institute
- Morgan, I. Soerjomataram, H. Rumgay, et al. (2022) The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology. DOI: 10.1053/j.gastro.2022.05.054
E. Abby, S.C. Dentro, M. W. J. Hall, et al. (2023) NOTCH1 mutations drive clonal expansion in normal esophageal epithelium but impair tumor growth. Nature Genetics. DOI: 10.1038/s41588-022-01280-z.
This research was part-funded by Wellcome and Cancer Research UK. A full acknowledgements list can be found in the publication.
Related blog posts
16 Feb 2020
Cancer across the animal kingdom
Cancer, ageing and somatic mutation rates across species.
What is a mutation?
A mutation is a change that occurs in our DNA sequence, either due to mistakes when the DNA is copied or ...
26 Jan 2023
‘Collateral damage’ from normal cell function may cause mutations that play a role in cancer
APOBEC1 enzyme likely responsible for two mutational signatures found in many cancers in small intestine
19 Jan 2023
Bowel cancer mutations that impact immunotherapy identified
Researchers used CRISPR and mini tumours to discover more about how cancer develops and responds to the body’s immune response.